Medical Equipment Industry Overview

The computed tomography (CT) scanners devices and equipment market consists of sales of computed tomography scanners devices and equipment and related services. CT scanners are used in the diagnosis of various diseases including cancer, bone related diseases, cardiovascular diseases, gynaecological diseases, urological diseases, and other diseases. CT scanners use computer-controlled X-rays to create images of the body. A CT scan is a three-dimensional method of scanning. The key product types include low end segment (single and dual slice CT scanners), mid end segment (multi slice scanners), and high-end slice segment (open versions, and cardiac CT scanners). The market covered in the computed tomography (CT) scanners devices and equipment market report is segmented by product type into low slice, medium slice, high slice; by application into oncology, neurology, cardiovascular, musculoskeletal, others; by end user into clinics, diagnostic services, hospitals. The global computed tomography (CT) scanners devices and equipment market is expected to decline from $7.97 billion in 2020 to $7.86 billion in 2021 at a compound annual growth rate (CAGR) of -1.4%. The decline is mainly due to deferment of various treatments due to the outbreak of COVID-19 that has led to fall in demand for the equipment. The CT scanners devices and equipment market is expected to reach $9.26 billion in 2025 at a CAGR of 4.2%. Rising prevalence of cancer and cardiovascular diseases are driving the computed tomography (CT) scanners devices and equipment market. According to the Centers for Disease Control and Prevention in the USA, the number of new cancer cases will go up by 24% in men and 21% in women by 2020 than in 2010. The rising need for early stage detection and prevention of these life-threatening diseases, increase the demand for proper diagnostics which poses as an opportunity for CT scan manufacturers. For instance, according to the American Heart Association; by 2035, 45.1% of the US population is projected to have some form of CVD. Total costs of CVD are expected to reach $1.1 trillion in 2035, with direct medical costs projected to reach $748.7 billion and indirect costs estimated to reach $368 billion. Effects of radiation and increasing health concerns hinders the computed tomography (CT) scanner devices and equipment market growth. Diagnostic imaging procedures use CT scanner devices that release electromagnetic waves or particles called 'ionizing radiation'. This radiation coming from manmade sources such as CT scans, nuclear medicine scans and PET scans carry major health hazards and risks. Low doses can cause cancer in the long run. Cancer is a leading cause of death worldwide, accounting for an estimated 9.6 million deaths in 2018. When doses exceed certain levels it causes skin burns and acute radiation syndrome. According to a global survey conducted by National Council on Radiation Protection and Measurements (NCRP), on radiation overexposure accidents, 2390 people were over exposed to radiation, out of which 190 died. Companies in the industry are integrating medical imaging with healthcare IT technology by providing digital access to improve patient safety, enhance healthcare facility and save patient time and money. The data from CT scans are being integrated with an image processing and communicating system such as picture archiving and communication system (PACS) that brings CT images from multiple systems into one interface. This enables radiologists to securely store, digitally transmit electronic images and clinically-relevant reports, and make use of a comprehensive database of images in order to give an accurate diagnosis. These are increasingly incorporated and used for clinical analysis, diagnosis and treatment in departments such as radiology, nuclear medicine imaging, cardiology, pathology, oncology and dermatology. For example, Carestream health is a company that makes PACS (Picture archiving communication system) machines that integrates images from different sources under one interface. An agreement has signed by Philips to acquire Carestream health in March 2019. In 2016, a regulation on radiation protection-computed tomography was made by Department OF Health (DOH), Washington, which was effective from July 2017. According to the regulation, CT scan device manufacturers are not allowed to make protocol changes or other software changes or any upgrades impacting the radiation dose or image quality. They need approval of the lead interpreting CT physician, technologist, or the medical physicist to allow appropriate changes. If any uncertainty in the device that emit ionizing radiation which are supposed to comply with the given performance standards related to machine organization and other important metrics. There can be a product recall, medical alert or any safety notice sent to the manufacturer. Therefore, the manufacturers of medical imaging devices should reduce their ionizing radiation levels effectively in order to minimize the costs, and reduce timelines for approval. The stringent regulations like these might affect the computed tomography scanner devices and equipment market. Major players in the computed tomography (CT) scanners devices and equipment market are GE Healthcare, Koninklijke Philips N.V., Hitachi Ltd., Siemens, Canon Medical Systems Corporation, Neusoft Medical Systems, Hitachi Healthcare America, Neurologica, Samsung Electronics, and Shimadzu Corporation. The regions covered in the computed tomography (CT) scanners devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the computed tomography (CT) scanners devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global computed tomography (CT) scanners devices and equipment market is segmented - 1) By Product Type: Low Slice, Medium Slice, High Slice 2) By Application: Oncology, Neurology, Cardiovascular, Musculoskeletal, Others 3) By End User: Clinics, Diagnostic Services, Hospitals

The trauma fixation devices and equipment market consists of sales of trauma fixation devices and equipment and related services. Trauma fixation devices and equipment are used in the treatment of patients suffering from physical trauma. They include internal fixation devices (plates and screws, intramedullary nails, compression hip screws, and cannulated screws) and external fixation devices (unilateral fixation, circular fixation, and hybrid fixation devices). The market covered in the trauma fixation devices and equipment market report is segmented by type into internal fixation devices, external fixation devices; by end user into hospitals, trauma centers, ambulatory surgical centers; by product type into metal plates and screws, pins/wires, nails and rods, circular fixator, hybrid fixator, unilateral fixator. The global trauma fixation devices and equipment market is expected to decline from $6.62 billion in 2020 to $6.32 billion in 2021 at a compound annual growth rate (CAGR) of -4.5%. The decline is mainly due to deferment of various bone treatments due to the outbreak of COVID-19 that has led to fall in demand for the equipment. The trauma fixation devices and equipment market is expected to reach $7.61 billion in 2025 at a CAGR of 4.8%. The trauma fixation devices and equipment market is driven by the increasing number of road accidents and sports injuries. According to WHO, approximately 1.35 million people die every year due to road traffic accidents. Also, around 20 to 50 million people suffer non-fatal injuries resulting in a disability. According to the National Safety Council (NSC), exercise and the use of exercise equipment led to the most injuries (526,000). Basketball players reported 500,000 injuries, whereas bicycling sports specialists accounted to 457,000 injuries and 341,000 injuries were recorded for football players. Rapid rise in road accidents and sports injuries are expected to drive the trauma fixation devices and equipment market during the forecast period. Increasing product recalls is one of the restraints for the trauma fixation treatment devices and equipment market. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, the company bears the cost of fixing the defective product and cost of replacement. This replacement cost of large number of products can go up to multi-million dollars, restraining the growth of the company and for the whole market as well. For example, in 2019, Brainlab AG recalled its spine and trauma 3D navigation software as the display was showing inaccurate details that could result in user misinterpretation during surgeries and harm the patient. Undertaking of strategic partnership and collaboration is the recent trend being followed by companies in the trauma fixation devices. This is due to the presence of a large number of vendors in the market, in order to maintain the market share in the competitive market and to enter into the new geographies, companies are making strategic partnerships with companies and Research Institutes. For example, In December 2018, Medtronic in partnership with Shandong Weigao Group opened an R&D center to develop orthopedic technologies and devices for the local market which in turn helps Medtronic to expand their operations in China. The stringent regulations and validations coupled with lengthy approval time by the US-FDA is restricting the trauma fixation devices and equipment. The US 510(k) regulatory process mandates that the manufacturers should prove that a device is substantially equivalent to a standard/earlier approved device before approval. The trauma fixation devices needs a much longer time to prove safety and efficacy as these devices needs to be checked for innovative areas such as materials research and biodegradation. The changes in validation testing has also made the device approval or QC process quite strenuous. In 2018, Medical Device Regulation (MDR) mandated implementation of two tests, ASTM F382 and ASTM F384 compulsory for all the trauma fixation devices in order to improve the performance and the quality of the devices. ASTM F382 is used to test the uniformity of the bone plate designs and ASTM F384 is used to compare the performance of the different angled designs. Major players in the trauma fixation devices and equipment market are Zimmer Biomet Holding Inc, Stryker Corporation, DePuy Synthes, Medtronic Plc, Smith & Nephew, B. Braun Melsungen AG, Medartis Holding AG, Arthrex Inc., Depuy Synthes (J&J), Medtronic PLC, Orthofix Holdings Inc., and Integra LifeSciences. The regions covered in the trauma fixation devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the trauma fixation devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global trauma fixation devices and equipment market is segmented - 1) By Type: Internal Fixation Devices, External Fixation Devices 2) By End User: Hospitals, Trauma Centers, Ambulatory Surgical Centers 3) By Product Type: Metal Plates and Screws, Pins/Wires, Nails and Rods, Circular Fixator, Hybrid Fixator, Unilateral Fixator

The disposable hospital supplies market consists of the sale of disposable hospital supplies and related services. Disposable hospital supplies are products manufactured for single usage and include supplies such as face masks, gowns and gloves among others. The global disposable hospital supplies market is expected to grow from $22.38 billion in 2020 to $26.72 billion in 2021 at a compound annual growth rate (CAGR) of 19.4%. The change in growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The disposable hospital supplies market is expected to reach $36.25 billion in 2025 at a CAGR of 8%. The disposable hospital supplies market covered in the disposable hospital supplies market report is segmented by type into gloves, drapes, gowns, needles, syringes, procedure kits and trays, bandages, masks. It is also segmented by product into diagnostic supplies, dialysis consumables, radiology consumables, infusion products, incubation & ventilation supplies, hypodermic products, sterilization consumables, non-woven medical supplies, wound care consumables, others; by end-user into hospitals, clinics/physician offices, assisted living centers & nursing homes, ambulatory surgery centers, research institutes. The increasing number of COVID-19 cases across the globe is projected to surge the demand for disposable hospital supplies. The rapid surge in coronavirus cases is generating huge demand for personal protective equipment (PPE) and other disposable supplies to protect healthcare workers from infections in their daily operations. According to the World Health Organization report published on the 3rd July 2020, there were 10,719,946 COVID-19 confirmed cases including 323,412 deaths globally. Therefore, the rise in the number of cases across the globe and the growing need for healthcare workers to be protected against the spread of the virus are anticipated to boost the demand for disposable hospital supplies market over the forecast period. The government agencies are extending support to PPE manufacturers and suppliers to ensure the smooth flow of medical supplies. For instance, UNICEF launched a joint tender in April for PPE supplies during 2020 on behalf of several UN organizations. The government initiatives to help medical supplies manufacturers and suppliers are likely to play a vital role in aiding the manufacture of essential medical supplies, which in turn, is predicted to shape the disposable hospital supplies market in the forthcoming years. Rising environmental concerns associated with the improper disposal of non-reusable hospital supplies is expected to limit the growth of the disposable hospital supplies market. In healthcare facilities, disposable gloves and gowns are widely used to maintain a sterile environment and reduce the risk of spreading infections during the pandemic. Improper disposal of supplies including gloves, gowns, masks and other personal protective equipment used during the monitoring and treatment of COVID-affected patients poses a high risk of virus spread. Environmental regulatory bodies are imposing stringent rules for proper and managed disposal of hospital wastes. For instance, in the USA, contaminated gloves are disposed of in orange-lidded containers or orange bags based on the law guidance laid by the Royal College of Nursing. The increase in production capacities by various players dealing in disposable hospital supplies market amid coronavirus outbreak is a leading trend shaping the growth of the industry. For instance, on 15th May 2020, Honeywell announced plans to build a new production line in Scotland, UK with the capacity of producing 4.5 million FFP3 and FFP2 disposable face masks every month. These masks are likely to assist the UK government’s response to the COVID-19 outbreak. Thus, the expansion of production capacities to meet the increased demand for disposable medical supplies is projected to generate higher revenues for the market during 2020. In April 2020, Eclipse Automation Inc. announced collaboration with Harmontronics Automation of Suzhou, China to manufacture, distribute and sell the Harmontronics fully automated N95 Vertical Flat-Fold Respirator Mask production line system across North America. Harmontronics Automation is a factory automation solution provider for small and precise product manufacturing. Major players in the disposable hospital supplies market are Abbott Laboratories, Bayer AG, Becton, Dickinson and Company, Cardinal Health Incorporated, Domtar Corporation, 3M, Stryker Corp, Hill-Rom Holdings Inc, Steris Corp, Getinge AB. The regions covered in the disposable hospital supplies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the disposable hospital supplies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global disposable hospital supplies market is segmented - 1) By Type: Gloves, Drapes, Gowns, Needles, Syringes, Procedure Kits And Trays, Bandages, Masks 2) By Product: Diagnostic Supplies, Dialysis Consumables, Radiology Consumables, Infusion Products, Incubation & Ventilation Supplies, Hypodermic Products, Sterilization Consumables, Non-Woven Medical Supplies, Wound Care Consumables, Others 3) By End-User: Hospitals, Clinics/Physician Offices, Assisted Living Centers & Nursing Homes, Ambulatory Surgery Centers, Research Institutes

The urinary incontinence and pelvic organ prolapse devices and equipment market consists of sales of urinary incontinence and pelvic organ prolapse devices and equipment and related services. Urinary incontinence and pelvic organ prolapse devices and equipment industry generates revenues by developing devices and equipment's used for the treatment of pelvic organ prolapse and urinary incontinence. Urinary incontinence (UI), also known as involuntary urination, is defined as an uncontrolled leakage of urine caused due to overactive bladder. It can affect both men as well as women. Pelvic organ prolapse (POP) is caused because of the defects in the supporting structures of the vagina. Depending on the size and location of the defect, the functions of the organs contained within the female pelvis can alter their normal functioning. The device market deals with medical devices such as Urinary Catheters, Vaginal Slings, External Urinary Incontinence Devices and others. The urinary incontinence and pelvic organ prolapse devices and equipment market covered in the report is segmented by type into urinary incontinence devices, pelvic organ prolapse devices; by urinary incontinence devices: artificial urinary sphincters, electrical stimulation devices, urethral slings, catheters; by pelvic organ prolapse devices into vaginal mesh, vaginal pessary; by incontinence type into stress incontinence, urge incontinence, overflow incontinence, functional incontinence; by end user into hospitals, clinics, ambulatory surgical centers, home use. The global urinary incontinence & pelvic organ prolapse devices and equipment market is expected to decline from $0.1 billion in 2020 to $0.09 billion in 2021 at a compound annual growth rate (CAGR) of -10%. The decline is mainly due to deferment of treatments due to the outbreak of COVID-19 that has led to fall in demand for the equipment. The urinary incontinence and pelvic organ prolapse devices and equipment market is expected to reach $0.13 billion in 2025 at a CAGR of 9.6%. Increased prevalence rate for pelvic organ prolapse (POP) as well as for urinary incontinence (UI) disorders has been driving the growth of urinary incontinence and pelvic organ prolapse devices and equipment market. The increasing prevalence rate has led the manufacturers towards developing more accurate and efficient devices for the treatment of these disorders. The POP affects women of all ages, however, the old age women are more prone to POP disorders. According to the US FDA reports, the number of women who have POP is expected to increase by 46%, to 4.9 million, by 2050. According to a report published by the American Urological Association (AUA/SUFU), the prevalence of stress urinary incontinence (SUI) in women was repoted to be as high as 49%. The prevalence rate of stress urinary incontinence is high in poor nutritional status group, as it results in weakness of pelvic supports. This high prevalence rate is driving the demand for medical equipment for urinary incontinence and pelvic organ prolapse. The urinary incontinence and pelvic organ proplapse devices and equipment market is being restrained by rising health issues due to the use of vaginal mesh for the treatment of UI and POP. Regulatory agencies such as FDA and NICE have devised new guidelines for the manufacturers to address these concerns. The vaginal mesh implants generally uses Polypropylene layer over the implants. Such vaginal mesh implants containing Polypropylene have caused severe medical complications in millions of women across the world, therefore, manufacturers are now forced to develop an alternative material, such as polyurethane, which is better suited to be used by women without any health complications for treatment of pelvic organ prolapse and urine incontinence. For instance, on March 8 2019, C.R. Bard, one of the major players of urinary incontinence and pelvic organ prolapse devices and equipment industry, announced its exit from the market of manufacturing and sale of vaginal mesh products in all markets worldwide after facing lawsuits from various women campaign groups across the globe. These concerns about the safety of vaginal mesh are resulting in stringent manufacturing regulations and affecting sales, thus restraining the UI and POP devices and equipment market. The urinary incontinence and pelvic organ proplapse devices and equipment industry is characterized by the increased use of several new technologies in recent years. There is a wide range of devices being developed to treat both POP and urinary incontinence. For instance, The Lyrette™ transurethral SUI system led by Verathon Medical UK Ltd, is the only FDA approved treatment used for treatment of stress urinary incontinence (SUI) among women. Devices such as such as Lyrette™ transurethral SUI system are used for procedures for incontinence. The treatment through Lyretter does not require the use of anesthesia or surgery instead it uses radiofrequency energy to tighten the tissue of the bladder. For the treatment of POP, companies are now focusing on using native tissue prolapse repair procedures instead of vaginal mesh after the adverse health issues from the usage of vaginal mesh were highlighted. Regulatory bodies, such as the FDA in the US, regulates the manufacturing and safety guidelines for devices and equipment related to urinary incontinence and pelvic organ prolapse disorders. For instance, manufacturers are required to obtain pre market clearance (510(k)) of the tools specifically for implanting surgical mesh. FDA requires the manufacturers in urinary incontinence and pelvic organ prolapse devices and equipment industry to conduct post market studies to check the specific safety and effectiveness concerns related to surgical mesh used for the repair of POP. For example, FDA regulations resulted in many companies taking down their product completely from the market and made companies like Coloplast and Acell to discontinue marketing of their products- Coloplast's Restorelle DirectFix Posterior and Acell Matristem's Pelvic Floor Repair Matrix respectively. Major players in the urinary incontinence and pelvic organ prolapse devices and equipment market are Boston Scientific Corporation, Coloplast Group, Ethicon US, Bard Inc., and Johnson & Johnson. The regions covered in the urinary incontinence and pelvic organ prolapse devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urinary incontinence and pelvic organ prolapse devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global urinary incontinence & pelvic organ prolapse devices and equipment market is segmented - 1) By Type: Urinary Incontinence Devices, Pelvic Organ Prolapse Devices 2) By Urinary Incontinence Devices: Artificial Urinary Sphincters, Electrical Stimulation Devices, Urethral Slings, Catheters 3) By Pelvic Organ Prolapse Devices: Vaginal Mesh, Vaginal Pessary 4) By Incontinence Type: Stress Incontinence, Urge Incontinence, Overflow Incontinence, Functional Incontinence 5) By End User: Hospitals, Clinics, Ambulatory Surgical Centers, Home Use

The benign prostatic hyperplasia (BPH) treatment devices and equipment market consists of sales of benign prostatic hyperplasia treatment devices and equipment and related services. Benign prostatic hyperplasia or benign prostatic hypertrophy is a condition of an enlarged prostate gland which causes blockade of urethra, the tube that carries urine from the bladder. The market is segmented into resectoscopes, radiofrequency ablation device, urology lasers, prostatic stents and implants. The market covered in the benign prostatic hyperplasia (BPH) treatment devices and equipment market report is segmented by product into resectoscopes, radiofrequency ablation device, urology lasers, prostatic stents, implants; by end-user into hospitals, ambulatory surgical centres (ASC), clinics, home; by procedure type into transurethral needle ablation (TUNA), transurethral resection of prostate (TURP), transurethral incision of prostate (TUIP), transurethral microwave thermotherapy (TUMT), laser surgery others. The global benign prostatic hyperplasia (BPH) treatment devices and equipment market is expected to decline from $2.1 billion in 2020 to $2.04 billion in 2021 at a compound annual growth rate (CAGR) of -2.9%. The decline is mainly due to deferment of treatments due to the outbreak of COVID-19 that has led to fall in demand for the equipment. The BPH treatment devices and equipment market is expected to reach $2.73 billion in 2025 at a CAGR of 7.6%. Benign Prostatic Hyperplasia (BPH) also called Prostate Gland Enlargement (PGE), is a condition where patient suffers from uncomfortable urinary symptoms. Due to rising prevalence of Benign Prostatic Hyperplasia, demand for BPH treatment devices and equipment is on a steady rise as the number of BPH cases increases the demand for devices will also increase. For example, in the USA by 2018, more than 8 million men are suffering from Benign Prostatic Hyperplasia (BPH) and globally around 22 million men have been diagnosed with moderate to severe symptoms of BPH. Therefore, with number of BPH cases on the steady rise, the demand for BPH treatment devices and equipment is also expected to grow. The side effects suffered by the patients after a BPH procedure is one of the major restraints for BPH device and equipment market. For example, most common side effects of a BPH surgery includes, urinary incontinence, discomfort during urination and difficulty in completely emptying the bladder. The patients suffering from BPH does not prefer surgical procedures (till the stage it can be avoided) due to these side effects, therefore decreasing the demand of surgical procedures, which in turn limits the demand for devices used by end users like hospitals, clinics and ambulatory surgical centers. Prostatic Astery Embolization (PAE) is one of the latest developments in the market for Benign Prostatic Hyperplasia (BPH) treatment device and equipment. PAE is a minimally invasive treatment that assists in reducing the symptoms observed in urinary tract. The PAE procedure is done using X-rays and other advanced imaging to observe the tumor inside the body and accordingly treat it without any surgery. This technique results in reduced complication in the treatment of BPH and thus is said to be a major development in the market of BPH treatment. Leading companies such as Boston scientifics, UNC healthcare, and Spire healthcare have been investing in the market for PAE. Product recall is a process of retrieving all faulty and defective products that have been sold or are available in the market. When a company recalls a product from the market, the company bears all the cost of fixing the defective product and cost of replacement. This cost of replacement for large companies can go up to multi-million dollar, hence restraining the growth of the company and for the whole market as well. Product recall is one of the major hurdles for any market, Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment market is no exception. For example, in the year 2019, Procept BioRobotics Corporation recalled its AquaBeam Handpiece, a part of its AquaBeam Robotic System due to the possibility of developments of internal leak because of micro-cracks in specific weld joints within the product device. In 2018, Boston Scientific acquired NxThera for an upfront cash payment of $306 million, and up to an additional $100 million in potential commercial milestone payments over the next four years. This acquisition will strengthen Boston’s already existing urology and pelvic health portfolio range. The acquisition of NxThera would be the best fit along with Boston Scientific’s laser therapy systems for the treatment of symptomatic BPH such as the Greenlight XPSTM Laser Therapy system and holmium platforms. NxThera, Inc.is involved in the manufacturing of medical devices to treat patients suffering from urologic conditions such as benign prostatic hyperplasia (BPH), prostate cancer, and kidney cancer. It was founded in 2008 and is headquartered in Minnesota, USA. Major players in the benign prostatic hyperplasia (BPH) treatment devices and equipment market are Karl Storz, Lumenis, Olympus, Urologix, and Boston scientific Inc. The regions covered in the benign prostatic hyperplasia (BPH) treatment devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the benign prostatic hyperplasia (BPH) treatment devices and equipment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global benign prostatic hyperplasia (BPH) treatment devices and equipment market is segmented - 1) By Product: Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants 2) By End-User: Hospitals, Ambulatory Surgical Centres (ASC), Clinics, Home 3) By Procedure Type: Transurethral Needle Ablation (TUNA), Transurethral Resection Of Prostate (TURP), Transurethral Incision Of Prostate (TUIP), Transurethral Microwave Thermotherapy (TUMT), Laser Surgery Others

The 3D printed medical implants market consist of sales of 3D printed medical implants and related services. In 3D printing technology, an artificial three dimensions physical object is created with the help of computer-aided design (CAD) or a magnetic resonance image (MRI), which can replaced the missing or defective body parts, to give support or recover damaged biological structure. 3D printed medical implants include 3D dental crowns, 3D dental bridges, 3D acetabular hip implants and shoulder implants. The 3D printed implants market covered in this report is segmented by application into dental, orthopedic, cranio-maxillofacial. The 3D printed medical implants market is also segmented by end users into medical and surgical centers, pharmaceutical companies, biotechnology industry, medical institution and by implantation technology into laser beam melting, electronic beam melting, droplet deposition, laminated deposition, two-photon polymerization. The global 3D printed implants market is expected to grow from $0.14 billion in 2020 to $0.15 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The 3D printed medical implants market is expected to reach $0.27 billion in 2025 at a CAGR of 15.8%. Increasing prevalence of various medical conditions is driving the growth of the 3D printed medical implants market. As the number of people suffering from orthopedic, cardiac and dental diseases is increasing, the demand for 3D dental crowns, 3D dental bridges, 3D acetabular hip implants and shoulder implants and various other implants is rising. According to the World Health Organization (WHO), the US had around 65 million people suffering from periodontitis i.e. Inflammation and infection of the ligaments and bones that support the teeth. This mainly occurred due to rising prevalence of periodontitis, diabetes-related gangrene, osteoarthritis, and peripheral vascular disease. Similarly, the rise in prevalence of other medical conditions is driving the demand for use of 3D printed medical implants. Stringent approval process for selection of a new material to be used in 3D implants is a time-consuming process that acts as a restraint for the 3D Printed Medical Implants market. 3D Printing requires high-quality materials that should adhere to specific criteria set by regulatory bodies such as US FDA. These regulatory bodies provide procedure guidelines, requirements, and monitor material quality control. For example, the US FDA approved spinal implants made from titanium alloy, but it didn't approve titanium alloy to be used in any other medical device. For each new use of the material, manufacturing companies needs to get the approval again from regulatory bodies. This causes a lag in the manufacturer's operational cycle and delays the product launch, thus affecting sales and restraining the growth of the 3D printed medical implants market. Many companies in this market are collaborating with various hospitals and rehabilitation centers to provide customizable devices for specific needs of patients. These collaboration are aimed to be mutually beneficial for both, as the companies can use the network of the hospitals to promote their product and the hospitals would get customizable devices at their convenience. For example, In January 2019, Renishaw, a global manufacturer of 3D implants, collaborated with University Dental Hospital of Wales (UDH), Cardiff, to help overcome challenges associated with surgical implants. This would help Renishaw to work with hospitals and become the major supplier of medical additive manufacturing devices. Similarly, in January 2019, Hospital for Special Surgery (HSS) collaborated with Lima Corporate to provide a 3D printed facility for orthopedic implants. This collaboration would help HSS to use Lima's technology to produce new innovative products for orthopedic joint care and to expand its product portfolio. The US FDA's Center for Devices and Radiological Health (CDRH) is the regulatory authority for companies who manufacture, repackage, relabel, and/or import medical devices sold in the United States. The medical devices made using 3D printing technology are subject to regulatory requirements before they are marketed (premarket requirements), and also after they are marketed (post market requirements). FDA classifies 3D printed medical devices into three classes, i.e., Class I, II, and III, with regulatory controls minimum for class I devices and maximum for class III devices. Most class III devices require premarket approval whereas class I devices are exempted from the approval. The manufacturers of 3D printed medical implants are required to establish and follow quality systems to ensure that their products consistently meet applicable requirements and specifications. The manufacturers also need to comply with FDA's standards regarding device design, manufacturing, and testing considerations during the development of 3D printed medical devices. In August 2018, Stryker acquired K2M for $1.4 billion.K2M, established in 2004 and headquartered at Leesburg, US, provides complex spinal implants and minimally invasive solutions focused on achieving three-dimensional body balance. Stryker aims to expand its product portfolio through this acquisition and achieve leadership in the spine and neurotechnology market. Major players in the 3D printed medical implants market are 3D Systems Corporations, Stratasys Ltd, Arcam AB, EnvisionTEC and SLM Solutions Group AG. The regions covered in the 3D printed medical implants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the 3D printed medical implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global 3D printed implants market is segmented - 1) By Application: Dental, Orthopedic, Cranio-maxillofacial 2) By End Users: Medical And Surgical Centers, Pharmaceutical Companies, Biotechnology Industry, Medical Institution 3) By Implantation Technology: Laser Beam Melting, Electronic Beam Melting, Droplet Deposition, Laminated Deposition, Two-photon Polymerization

The cell culture consumables and equipment global market consists of sales of cell culture consumables, equipment and related service. Cell culture consumables include sera, media, reagents, and equipment such as bioreactors, cell counters, filtration systems, centrifuges, and incubators. The services includes only installation and maintenance services offered by equipment manufacturers. Cell culture consumables and equipment are designed to aid scientist in growing new cells in the culture media for drug development, tissue culture, and engineering, gene therapy, vaccine production and toxicity testing. The cell culture consumables and equipment market covered in this report is segmented by product into consumables, instruments. The cell culture consumables and equipment global market is also segmented by end user into industrial, biotechnology, agriculture, others; by application into vaccination, toxicity testing, cancer research, drug screening and development, recombinant products, stem cell technology, regenerative medicine, others; by consumables into media, sera, reagents; by instruments into cell culture vessels, bioreactors, biosafety cabinets, carbon dioxide incubators, centrifuges. The global cell culture consumables and equipment market is expected to grow from $8.55 billion in 2020 to $9.46 billion in 2021 at a compound annual growth rate (CAGR) of 10.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cell culture consumables and equipment global market is expected to reach $13.49 billion in 2025 at a CAGR of 9.3%. Increase in prevalence of chronic diseases is driving the growth of cell culture consumables and equipment market. Chronic diseases such as cancer, diabetes, heart diseases, obesity and hypertension are growing rapidly. A few chronic diseases are caused due to loss or damage of certain type of cells. Such diseases can be cured by replacing the destroyed cells with new ones that are produced by pluripotent stem cells, using cell culture consumables and equipment. So, with the rising incidence of chronic diseases, there is an increased need for such equipment that can produce new cells outside the natural environment, thus driving the growth for this market. For example, according to the World Health Organization, chronic disease prevalence is expected to rise by 57% by the year 2020. Contamination of cell culture is the most prominent factor restricting the growth of cell culture consumables and equipment market. Contaminated culture is the presence of non-living substances or unwanted foreign microorganisms that have undesirable effects on the cell culture. Using contaminated culture cells has a number of negative consequences on the users and thus hampers the growth of this market. For example, an article published on MedCrave, stated that Mycloplasma is one of the most common and difficult to detect contaminants. The article also highlighted the results of a study on fibroblasts and keratinocyte cell lines that showed 32.35% of contamination, out of which 17.65% were mycoplasma contaminated cultures, followed by fungal (8.82%) and bacterial (5.88%) contaminants. Hence, the high risk associated with cell culture techniques pose a threat to the growth of cell culture consumables and equipment market. Companies in cell culture consumables and equipment are investing more in 3D cell culture for its new and advantageous features. 3D cell culture may be defined as the culture of living cells within micro-assembled devices and supports that present a three dimensional structure and are used to replicate a tissue or an organ in an artificial environment by allowing the cells to interact with the surroundings in all three directions. 3D cell cultures are more relevant with higher degree of structural complexity and maintains the steady state for more time as compared to 2D cell cultures. Visikol launched OpenLiver 3D cell culture models in January 2019 to enter into 3D cell culture technology. FDA regulates the cell culture consumables and equipment in the U.S. Under title 21, Sec 864.2240. For cell and tissue culture equipment FDA states that if the equipment is not labelled or mentioned as sterile, they would be removed from good manufacturing practice of the quality system. Additionally, each manufacturing unit should maintain procedures to receive, review, and evaluate complaints. These procedures require consistency and punctuality along with the documentation of the receipts. Therefore, these regulatory standards improves the safety and efficacy of instruments and consumables used during cell culture processes. Thermo Fisher acquired Brammer Bio for $1.7 billion in March 2019. Brammer Bio is a contract development and manufacturing organization (CDMO) for cell and gene treatment centered biotechs. This transaction will strengthen Thermo Fisher to grow faster and expand cell culture market in other countries. Brammer Bio is formed through the merger of Florida Biologix and Brammer Biopharmaceuticals in March 2016 and is headquartered in Cambridge, MA. Major players in the cell culture consumables and equipment global market are Becton Dickinson, Corning Incorporation, Eppendorf, GE Healthcare and Merck KGaA. The regions covered in the cell culture consumables and equipment global market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell culture consumables and equipment global market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global cell culture consumables and equipment market is segmented - 1) By Product: Consumables, Instruments 2) By End User: Industrial, Biotechnology, Agriculture, Others 3) By Application: Vaccination, Toxicity Testing, Cancer Research, Drug Screening and Development, Recombinant Products, Stem Cell Technology, Regenerative Medicine, Others 4) By Consumables: Media, Sera, Reagents 5) By Instruments: Cell Culture Vessels, Bioreactors, Biosafety Cabinets, Carbon Dioxide Incubators, Centrifuges

The hospital-acquired infections testing kits market consists of sales of hospital-acquired infections testing kits, devices and related services. Hospital acquired infections testing kits are used to check the infections associated with pathogens such as vancomycin-resistant enterococci (VRE), methicillin-resistant staphylococcus aureus (MRSA), multi-resistant gram-negative bacilli, norovirus, and clostridium difficile. The hospital acquired infections testing kits market covered in this report is segmented by product into instrument & reagents, consumables. The hospital-acquired infections testing kits market is also segmented by test type into pneumonia infection, urinary tract infection, blood stream associated infection, surgical site infection, MRSA infection, others; by application into drug-resistance testing, disease testing; by pathogen type into viral, bacterial, fungal and by method of treatment into sterilization, chemical, radiation. The global hospital acquired infections testing kits market is expected to grow from $0.9 billion in 2020 to $1 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The hospital-acquired infections testing kits market is expected to reach $1.49 billion in 2025 at a CAGR of 10.5%. The hospital-acquired infections (HAIs) are on the rise, affecting both the inpatients and outpatients. Hospital acquired infections or nosocomial infections are diseases that are acquired in hospitals and medical clinics. For example, according to the findings by Center for Disease Control and Prevention, around 1.7 million people in the USA acquire hospital-acquired infections caused while being admitted for other health issues and more than 98,000 (around 5%) patients die due to these infections. The increasing incidence of hospital-acquired infections leads to an increase in the demand for hospital acquired infections testing kits. Most of the underdeveloped and developing nations lack proper health insurance that covers essential health services. According to a report by the World Bank and the World Health Organization, more than 50% of the world’s population cannot avail essential health services due to expensive healthcare services that pushes them to poverty. For instance, 800 million people spend more than 10% of their household budgets on health expenses for themselves, a sick child or other family member and for almost 100 million people these expenses are high enough to push them into extreme poverty. This lack of financially affordable healthcare hinders the market growth for diagnostic services including hospital acquired infection testing. The diagnostic tests involved in diagnosing HAIs such as flow cytometry, mass spectrometry, near-infrared spectroscopy, nucleic acid-based technologies are advancing in technologies, providing more accurate data. There has been a significant advancement in mass spectrometers, which quantifies known materials, and identifies unknown compounds within a sample. For instance, SCIEX’s X500 QTOF solves the challenge of contamination and is a compact device that does not compromise on resolution and accuracy. It gives results sooner and allows the operator to make data-driven decisions sooner. The market for hospital acquired infections testing kits is regulated by government agencies such as US FDA (Food and Drug Administration) in the USA, and the European Medicines Agency/Committee in European Region. The regulatory body lays down a set of guidelines pertaining to safety, efficiency and efficacy of the instruments that form part of the hospital acquired infection testing kits market. The manufacturers and service providers must comply with the CBER Regulations that have been published in the first chapter Title 21 of CFR. Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment and role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose. CBER comes under FDA (Food and Drug Administration). Also, Code of Federal Regulations Title 21, Part 866 states regulations pertaining to immunology and microbiology devices. These devices are used to identify infections caused due to bacteria and various viruses. Major players in the hospital-acquired infections testing kits market are Becton, Dickinson and Company, Abbott Laboratories, Cepheid, F. Hoffmann-La Roche Ltd., and Hologic. The regions covered in the hospital-acquired infections testing kits market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hospital-acquired infections testing kits market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global hospital acquired infections testing kits market is segmented - 1) By Product: Instrument & Reagents, Consumables 2) By Test Type: Pneumonia Infection, Urinary Tract Infection, Blood Stream Associated Infection, Surgical Site Infection, MRSA Infection, Others  3) By Application: Drug-Resistance Testing, Disease Testing 4) By Pathogen Type: Viral, Bacterial, Fungal 5) By Method of Treatment: Sterilization, Chemical, Radiation